

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	9009-0001-03	Appln. No.	Continuation of Appln No. 10/223,850 10/824,609
Applicant	Ae Ri Kim et al.		
Filing Date	April 15, 2004	Prior Group:	1625

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
mgd	A1	4,931,446	06/05/1990	Berger-Neel, et al.			
	A2	5,286,723	02/15/1994	Hayakawa et al.	514	213	
	A3	5,508,428	04/16/1996	Hayakawa et al.	548	408	
	A4	5,633,262	05/1997	Hong et al.	514	300	
	A5	5,698,570	12/16/1997	Hong et al.	514	312	
	A6	5,776,944	07/1998	Hong et al.	514	300	
	A7	5,840,916	11/24/1998	Hong et al.	548	557	
	A8	5,869,670	02/09/1999	Hong et al.	546	123	
	A9	5,962,468	10/05/1999	Hong et al.	514	300	
mgd	A10	6,307,059	10/04/2001	Chang, et al.			

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
mgd	B1	183129	06/04/1986	EP			
	B2	266576	05/11/1988	EP			
	B3	326891	08/09/1989	EP			
	B4	541086	05/12/1993	EP			
	B5	1-100165	04/18/1989	JP			English abstract only
	B6	WO 91/02526	Mar. 7, 1991	PCT			
	B7	WO 93/25545	Dec. 23, 1993	PCT			
	B8	0688772A1	Dec. 27, 1995	EP			
	B9	CN 1114959 A	Jan., 1996	China			
	B10	WO 96/23775	Aug. 8, 1996	PCT			EP 787720 is enclosed.
	B11	WO 96/39406	Dec. 12, 1996	PCT			
mgd	B12	EP 787720	Aug. 6, 1997	EP			

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 9009-0001-03	Appln. No. Continuation of Appln No. 10/223,850 10/824,609
Applicant Ae Ri Kim et al.	
Filing Date April 15, 2004	Prior Group: 1625

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
ind	B3	WO 00/17199	Mar. 30, 2000	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
ind	Ahn, et al., "Effect of a New Fluoroquinolone LB20304a on Microflora of Caecum of Mice," <i>Yakhak Hoeji</i> , 40(3): 343-346 (1996). English translation.
	Ahn, Mi-Jeong et al., "Post-Antibiotic Effect of LB20304, A New Quinolone Antibiotic," <i>Yakhak Hoeji</i> , 1996, 40(3): 347-350. English translation.
	Ahn, et al., "In vivo Efficacy of LB20304a against Experimental Respiratory Tract Infection in Mice," <i>Yakhak Hoeji</i> , 40(4): 438-441 (1996). English translation.
	Biedenbach et al., "Antimicrobial Activity of LB20304 Against Legionella species and Anaerobic Bacteria Using Reference Agar Dilution Methods," <i>Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , Abstract F-170 (1997).
	Bouzard et al., "Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure-Activity Relationships of 5-Substituted-6-fluoro-7-(cycloalkylamino)-1, 4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acids," <i>J. Med. Chem.</i> , 35: 518-525 (1992).
	Bryskier, "Update, Anti-infectives, Novelties in the Field of Fluoroquinolones," <i>Exp. Opin. Invest. Drugs</i> 6(9): 1227-1245 (1997).
	Chu, "Section Review: Anti-infectives, The Future Role of Quinolones," <i>Exp. Opin. Ther. Patents</i> 6(8): 711-737 (1996).
	Cormican, et al., "Comparative Antimicrobial and Spectrum Activity of LB20304a, a New Fluoronated Naphthyridone Compound," <i>Abstracts of the 36th ICAAC</i> , 36: 109, Abstract F53(1996).
	Cormican, et al., "Antimicrobial Activity and Spectrum of LB20304, a novel Fluoronaphthyridone," <i>Antimicrobial Agents and Chemotherapy</i> , 41(1): 204-211 (1997).
	Hawley's Condensed Chemical Dictionary, twelfth ed., Van Nostrand Reinhold Company: 609 and 1031 (see highlighted portions).
	Hohl, et al., "International multicenter investigation of LB20304, a new fluoranaphthyridone," <i>Clin., Microbiol. Infect.</i> 4: 280-284 (1998).
	Hong, et al., "Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl)pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-Aminomethyl)-3-methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1.8]naphthyridine-3-carboxylic Acid (LB20304)," <i>J. Med. Chem.</i> 40: 3584-3593 (1997).
ind	Kim, Mu-Yong, et al. "In vitro activities of LB20304, a new fluoroquinolone," <i>Arch. Pharmacol Res.</i> (1996), 19(1), pp. 52-59.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	9009-0001-03	Appln. No.	Continuation of Appln No. 10/223,850 10/824,609
Applicant	Ae Ri Kim et al.		
Filing Date	April 15, 2004	Prior Group:	1625

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
↑	Kwak, et al., "Antimicrobial Activities of LB20304a, a New Quinolone Antibiotic," <i>The Journal of Applied Pharmacology</i> , <u>4</u> : 378-384 (1996).
	Marco, et al., "Antimicrobial Activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria," <i>J. Antimicrob. Chemother.</i> <u>40</u> : 605-607 (1997).
	Oh, Jeong-In, et al. "In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone," <i>Antimicrob Agents Chemother.</i> (1996), 40(6), pp. 1564-1568.
	Paek, Kyoung-Sook, et al. "Factors affecting in vitro activity of LB20304, a new fluoroquinolone," <i>Arch. Pharm. Res.</i> , 1996, 19(2), 143-147.
	Paek, Kyoung-Sook, et al. "Bactericidal activities of LB20304, a new fluoroquinolone," <i>Arch. Pharmacol Res.</i> (1996), 19(4), pp. 317-320.
	Seo, et al., "High Performance Liquid Chromatographic Assay of a New Fluoroquinolone, LB20304, in the Plasma of Rats and Dogs," <i>Arch. Pharm. Res.</i> , <u>19</u> (6): 554-558 (1996).
	Seo, et al., "Pharmacokinetics of LB20304, a New Fluoroquinolone, in Rats and Dogs," <i>Arch. Pharm. Res.</i> , <u>19</u> (5): 359-367 (1996).
	Seo, et al., "Pharmacokinetics of a New Quinolone LB20304a, In Rats and Dogs," <i>Annual Meeting of the American Association of Pharmaceutical Scientists Seattle</i> , <u>13</u> (9): S-486, Abstract PPDM 8374 (1996).
↓	Stedman's Medical Dictionary, 26 th ed., Williams & Wilkins: 814 and 1604 (see highlighted portions).
↑	The Oxford Dictionary for Scientific Writers and Editors, Clarendon Press: 179 and 312 (see highlighted portions).

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 9009-0001-03	Appln. No. Continuation of Appln No. 10/223,850 23 10/824,609
Applicant Ae Ri Kim et al.	
Filing Date April 15, 2004	Prior Group: 1625

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
nd	Cooper et al., "Preparation and in Vitro and in Vivo Evaluation of Quinolones with Selective Activity Against Gram-Positive Organisms", <i>J. Med. Chem.</i> , 35: 1392-1398 (1992).
	Domagala et al., "1-Substituted 7-[3-[(Ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acids. New Quantitative Structure-Activity Relationships at N ₁ for the Quinolone Antibacterials," <i>J. Med. Chem.</i> , 31: 991-1001 (1988).
	Domagala et al., "Synthesis and Biological Activity of 5-Amino-and 5-Hydroxyquinolones, and the Overwhelming Influence of the Remote N ₁ -Substituent in Determining the Structure-Activity Relationship", <i>J. Med. Chem.</i> , 34: 1142-1154 (1991).
	Garau, "The Role of Quinolones in the Treatment of Community-Acquired Pneumonia," <i>Medicina Clinica</i> , 110 (Supp. 1): 31-35 (February 1998). English abstract only.
	Kim et al., "Phototoxicity studies of LB20304a," <i>Korean J. Vet. Pathol.</i> , 1: 40-45 (1997). English translation.
	Kim et al., "General Pharmacology of LB20304a, a New Quinolone Antibiotic," <i>The Journal of Applied Pharmacology</i> , 4(2): 184-189 (1996). English translation.
	Kim et al., "Bacterial Resistance to LB20304, a New Fluoroquinolone Antibiotic," <i>Arch. Pharm. Res.</i> , 19(5): 400-405 (1996).
	Kim et al., "Novel 6-Methylquinolone Antibacterials: A New Class of Non-6-Fluoroquinolones," <i>Korean J. of Med. Chem.</i> , 7(1): 19-22 (1997).
	Kim et al., "Safety Evaluation of LB20304, a New Quinolone Antibiotic," <i>The Journal of Applied Pharmacology</i> , 3(4): 322-326 (1995).
	Kim et al., "Synthesis and Antibacterial Activities of LB20304: A New Fluoronaphthyridone Antibiotic Containing Novel Oxime Functionalized Pyrrolidine," <i>Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , Session 122, Abstract F204, 148 (1995).
	Koga et al., "Structure-Activity Relationships of Antibacterial 6,7- and 7,8-Disubstituted 1-Alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic Acids", <i>J. Med. Chem.</i> , 23: 1358-1363 (1980).
	Leshner et al., "1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents", <i>J. Med. Chem.</i> , 5: 1063-1065 (1962).
nd	Matsumoto et al., "AT-3295, a New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure-activity Relationships", <i>Proceedings of the 14th International Congress of Chemotherapy</i> , 1519-1520 (1985).

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 9009-0001-03	Appln. No. Continuation of Appln No. 10/283,850 10/824,609
Applicant Ae Ri Kim et al.	
Filing Date April 15, 2004	Prior Group: 1625

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
msb	Nam et al., "New Quinolone Antibacterial Agents Introducing New Functional Groups at C-3 Position," <i>Korean J. Med. Chem.</i> , 6(2): 203-238 (1996).
	Oh et al., "In vitro and In vivo Antibacterial Activities of LB20304, a New fluoronaphthyridone," <i>Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy</i> , Session 122, Abstract F205, 148 (1995).
	Parikh and von E. Doering, "Sulfur Trioxide in the Oxidation of Alcohols by Dimethyl Sulfoxide", <i>JACS</i> , 89: 5505-5507 (1967).
	Rosen et al., "Design, Synthesis, and Properties of (4S)-7-(4-Amino-2-substituted-pyrrolidin-1-yl) quinolone-3-carboxylic Acids", <i>J. Med. Chem.</i> , 31: 1598-1611 (1988).
	Sato et al., "In Vitro and In Vivo Activity of DL-8280, a New Oxazine Derivative", <i>Antimicrob. Agents Chemother.</i> , 22: 548-553 (1982).
	Sharma et al., "Fluoroquinolones: Antimicrobial Agents of the 90's," <i>Indian Journal of Pharmacology</i> , 26: 249-261 (1994).
	Wise et al., "In Vitro Activity of Bay 09867, a New Quinoline Derivative, Compared with Those of Other Antimicrobial Agents", <i>Antimicrob. Agents Chemother.</i> , 23: 559-564 (1983).
	CA 114: 164195r, 775 (1991).
msb	CA 119: 203318h, 884 (1993).

Examiner <i>Anna D. Quinn</i>	Date Considered <i>10/11/2005</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce